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RESUMO 
 
 
Na doença de Parkinson, a perda progressiva de neurónios produtores de 
dopamina da substantia nigra pars compacta conduz a desequilíbrios 
neuroquímicos da gânglia basal e, consequentemente, ao surgimento de 
sintomas como bradicinesia, rigidez das extremidades e tremor. Sintomas 
reminiscentes destas disfunções motoras, assim como sinais não motores de 
doença de Parkinson, foram revelados num modelo transgénico de murganho, 
modelo este que expressa apenas 5% da proteína transportadora vesicular 
monoaminérgica (VMAT2-deficient). A doença de Parkinson é tipicamente 
tratada com o fármaco L-DOPA, um percursor da dopamina. Dado que a 
degradação da molécula de L-DOPA pela enzima catecol-O-metiltransferase 
(COMT) leva ao aumento dos níveis de homocisteína, um fator de risco 
cardiovascular e demência, a reposição terapêutica prolongada de dopamina 
poderá acelerar a disfunção neuronal e a neurodegeneração. Para além do uso 
de L-DOPA, tentativas anteriores para restaurar os níveis de dopamina e 
simultaneamente promoverem neuroprotecção não foram bem-sucedidas. Este 
estudo investigará os efeitos do inibidor enzimático da enzima COMT, 
Tolcapone, nas funções motoras, nas performances olfactiva e cognitiva, e mais 
tarde, na evolução dos marcadores bioquímicos de neurodegeneração e dos 
níveis sanguíneos de homocisteína em murganhos VMAT2-deficient. Propõe-
se que o fármaco Tolcapone possa não só reduzir a degradação de L-DOPA mas 
adicionalmente favorecer o tratamento da doença de Parkinson aumentando e 
estabilizando os níveis de dopamina. Além disso, sugere-se ainda que a 
inibição farmacológica da enzima COMT oferece benefícios significativos a 
longo-prazo no contexto da doença de Parkinson: reduz o risco de episódios 
cardiovasculares, atrasa o aparecimento de declínio cognitivo, e sobretudo, 
oferece significativos efeitos neuroprotetores. 
 
Palavras-chave: doença de Parkinson, inibição de COMT, 
neurofarmacologia, modelo animal de PD, comportamento. 
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ABSTRACT 
 
 
In patients with Parkinson’s disease, the progressive loss of dopamine-
producing cells in the substantia nigra pars compacta leads to a neurochemical 
imbalance in the basal ganglia and finally to bradykinesia, rigidity and tremor. 
Symptoms reminiscent of these motor dysfunctions, as well as of non-motor 
signs of Parkinson’s disease, were revealed in transgenic mice with 5% 
expression of vesicular monoamine transporter 2 (VMAT2-deficient mice). PD 
is typically treated with dopaminergic drugs, in particular L-DOPA. Because 
methylation of L-DOPA by catechol-O-methyltransferase (COMT) leads to 
increased concentration of homocysteine, which is a known risk factor of 
vascular events and cognitive impairment, dopamine replacement may 
accelerate neuronal dysfunction and neurodegeneration. Previous attempts to 
restore striatal dopamine apart from L-DOPA and provide neuroprotection 
remained unsuccessful. As a novel approach, this study proposes to investigate 
the effects of the COMT inhibitor, Tolcapone, on motor function, olfactory and 
cognitive performances, and later, on biochemical markers of 
neurodegeneration and marker substances of homocysteine metabolism in 
peripheral blood in VMAT2-deficient mice. It is hypothesized that Tolcapone 
may not only inhibit the degradation of L-DOPA but further improve PD 
treatment by increasing and stabilizing serum dopamine concentrations, and 
ultimately, show in prospective manner whether pharmacological inhibition of 
COMT offers significant benefit in Parkinson’s disease context by reducing risk 
of vascular events and cognitive decline, and exerts neuroprotective effect.  
 
Key words: Parkinson’s disease, COMT inhibition, neuropharmacology, PD 
mouse model, behaviour. 
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CHAPTER 1 
INTRODUCTION 
 
 
1.1. DOPAMINE FUNCTIONS AND METABOLISM 
 
Dopamine (DA) is a hormone and one of the primary catecholamine 
neurotransmitters present in the mammalian brain. The study of 
catecholamine neurons started in the 1960s, when Carlsson, Falck and Hillarp 
used new methods to first describe norepinephrine (NE) and DA in discrete 
neuronal systems (Carlsson et al., 1964; Falck et al., 1982). 
The amino acid tyrosine (Tyr) is the precursor of DA and undergoes 
hydroxylation into l-dihydroxyphenylalanine (L-DOPA), a reaction catalyzed 
in the cytosol by the rate-limiting enzyme tyrosine hydroxylase (TH) together 
with molecular oxygen (O2), ferrous iron (Fe2+) and tetrahydrobiopterin 
(BH4) as cofactors. Afterwards, L-DOPA is decarboxylated into DA, a 
conversion catalyzed by the aromatic amino acid decarboxylase (AADC) and 
the cofactor pyridoxal phosphate that generates carbon dioxide (CO2) 
(Daubner et al., 2011).  
DA activity underlies multiple brain functions including locomotor 
activity, food intake, cognition, motivation, positive reinforcement and 
endocrine regulation, as well as it is also involved in the peripheral system as 
a modulator of both cardiovascular and renal functions, gastrointestinal 
motility (GI), hormone secretion, and vascular tone (Missale et al., 1998).  
The dopaminergic neurons synthesize, store and release DA to the 
synaptic space. They are confined to several small brain areas, primarily the 
ventral tegmental area (VTA) and the substantia nigra (SN), from where they 
extend axonal projections to distal brain regions, such as the striatum, the 
limbic system and the prefrontal cortex (PFC) (Björklund and Dunnett, 
2007). 
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 VESICULAR MONOAMINE TRANSPORTER 2 1.1.1.
 
Associated with TH and AADC is the vesicular monoamine 
transporter-2 (VMAT2), a 12-transmembrane domain proton-pumping 
adenosine triphosphatase (H+-ATPase) antiporter that transports DA 
synthesized in the cytosol (or recycled from the extracellular space) into small 
synaptic and dense core vesicles (Figure 1.1). Together they assemble a 
complex (TH-AADC-VMAT2) that converts Tyr to L-DOPA and L-DOPA to 
DA. Then, DA is taken up into vesicles (Cartier et al., 2009), preventing its 
spontaneous oxidation at physiological pH (pH 7.4) to neurotoxic DA-O-
quinone, superoxide radicals (O2•−) and hydrogen peroxide (H2O2). H2O2 is 
precursor of cytotoxic hydroxyl radicals (•−OH), catalyzed by copper (Cu+) or 
Fe2+, found in particular high concentrations in the SN pars compacta (SNpc) 
than in other brain regions. 
 
 
 
Figure 1.1 – Cytosolic DA sequestration dependent on VMAT2 
transporter. The intrasynaptic vesicle contain an ATPase that hydrolyzes ATP to 
ADP and Pi, translocating one proton (H+) into the vesicle and triggering a proton 
gradient. VMAT2 uses this proton gradient across the vesicular membrane as the 
driving force to take up one positively charged molecule of DA with the concomitant 
release of two H+. (ADP: adenosine diphosphate; ATP: adenosine triphosphate; 
ATPase: adenosine triphosphatase; Pi: inorganic phosphate; VMAT2: vesicular 
monoamine transporter-2). Modified from Chaudhry and colleagues (Chaudhry et 
al., 2008). 
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The increase of H+ inside these vesicles induces a decrease in the pH at 
the inner environment, which is estimated to be 2 to 2.4   pH units lower 
than that of the cytosol (Guillot and Miller, 2009) preventing the protons of 
the DA hydroxyl groups to dissociate from the oxygen. 
 Later on, soluble NSF attachment receptors (SNARES) and a series of 
protein complexes drive the DA-loaded vesicle to the plasma membrane, 
perform the docking and prime the vesicle for membrane fusion and 
exocytotic release (Li and Chin, 2003). Thus, VMAT2 is a crucial intracellular 
regulator of both the size of the vesicular DA pool and the availability of DA in 
the cytosol. In addition, VMAT2 is liable for interacting with several 
exogenous and endogenous toxins that appear to gain access to the 
dopaminergic neuron and ultimately impact its function and survival. VMAT2 
is present all through the central nervous system (CNS), where it is also 
responsible for regulating and packaging serotonin (5-HT), NE, epinephrine 
and histamine in their respective neuronal systems (Erickson et al., 1996), 
and in the periphery in mast cells and platelets.  
 
 
  DA DYNAMICS: DAT, MAO AND COMT 1.1.2.
 
The balance between the quantity of DA released, the duration of 
effects, and the responsiveness of postsynaptic receptors is crucial for the DA 
signaling dynamics. DA transporter (DAT), an exclusive symporter of 
dopaminergic neurons and member of the sodium/chloride-coupled (Na+/Cl−) 
neurotransmitter transporter family, plays an important part in regulating the 
duration of action of DA in the extracellular space, as well as in maintaining 
the delicate stability between DA synthesis, release, recycling and degradation 
(Jones et al., 1997) (Figure 1.2). This way, inhibition of DAT reduces DA 
reuptake and consequently increases its extracellular and synaptic 
concentrations as well as its lifespan, which leads to a prolonged stimulation 
of both postsynaptic and presynaptic DA receptors (D1-D5) (Kuhar, 1992). 
Monoamine oxidase (MAO) is a mitochondrial outer membrane-bound 
flavoenzyme found in neurons and glia cells. It catalyzes the oxidative 
deamination of the cytosolic DA amino group to 3,4-
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dihydroxyphenylacetaldehyde (DOPAL, non-toxic metabolite) along with 
formation of ammonia (NH3) and H2O2. DOPAL is further oxidized by 
aldehyde dehydrogenase (AD) to non-toxic 3,4-dihydroxyphenylacetate 
(DOPAC) (Binda et al., 2011), which can be further converted to homovanillic 
acid (HVA) catalyzed by catechol-O-methyltransferase  ( COMT).  
 
 
 
Figure 1.2 – DA sequestration, release, reuptake and breakdown. The DA 
present in the synaptic cleft is co-transported with two sodium ions (Na+) and one 
chloride ion (Cl-) into presynaptic terminals, as a result of the ion concentration 
gradient that is generated by the plasma membrane sodium-potassium adenosine 
triphosphatase (Na+/K+-ATPase). This recycled DA constitutes also a source of free 
cytosolic DA and can be sequestered again in monoaminergic vesicles. DA that was 
not immediately packaged inside presynaptic neurons is taken up by surrounding 
glial cells and gets degraded by COMT and MAO enzymes. (3-MT: 3-
methoxytyramine; AADC: aromatic amino acid decarboxylase; DAT: DA trasporter; 
DOPAC: 3,4-dihydroxyphenylacetate; DR: DA receptor; COMT: catechol-O-
methyltransferase; HVA: homovanillic acid; MAO: monoamine oxidase; TH: tyrosine 
hydroxylase). Modified from Sun and colleagues (Sun et al., 2014). 
 
COMT is a magnesium-dependent intracellular enzyme discovered by 
Axelrod and coworkers (Axelrod and Tomchick, 1958) present both in the 
brain and in the periphery, mainly the liver.  It catalyzes the methylation of 
catechol substrates (for instance L-DOPA) using S-adenosyl-L-methionine 
(SAM) as a methyl donor, resulting O-methylated catechol (such as 3-
methoxy-4-hydroxy-L-phenylalanine [3-OMD], from L-DOPA) and S-
adenosyl-L-homocysteine (SAH) as reaction products. When DA floods into 
L-DOPA 
AADC 
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the synaptic space and does not bind to receptors or is not taken back into the 
neuron via DAT, it gets degraded into 3-methoxytyramine (3-MT) by COMT 
and further metabolized by MAO to HVA (Figure 1.3).  
 
 
Figure 1.3 – Metabolism of L-DOPA. (AADC: aromatic amino acid 
decarboxylase; COMT: catechol-O-methyltransferase; DOPAC: 3,4-
dihydroxyphenylacetic acid; HVA: homovanillic acid; MAO: monoamine oxidase; 3-
MT: 3-methoxytyramine; 3-OMD: 3-O-methyldopa). Modified from Leegwater-Kim 
and Waters, (Leegwater-Kim and Waters, 2006). 
 
Human COMT is present in two distinct isoforms: membrane-bound 
(MB-COMT), which is the predominantly expressed form in the mammalian 
CNS and it is localized in the rough endoplasmic reticulum, and soluble (S-
COMT), found primarily in the cytoplasm of glial cells and peripheral tissues, 
such as the liver. Although MB-COMT and S-COMT share similar affinities 
for SAM, they have significantly different affinities for substrates such as DA 
(Espinoza et al., 2012). 
Degradation of DA by COMT might be a key process in the regulation 
of its availability at certain brain sites, such as the prefrontal cortex (PFC), 
L-DOPA 
L-DOPA 
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where DAT low expression within synapses turns DA uptake slower 
(Wayment et al., 2001) compared to the striatum, where it is able to terminate 
the synaptic action of DA by rapid neuronal uptake (Giros et al., 1996). 
 
 DOPAMINE DYSREGULATION 1.1.3.
 
DA imbalances and dysregulation of dopaminergic neurotransmission 
are linked to several neuropsychiatric and neurological conditions such as 
Parkinson’s disease (PD), schizophrenia, Tourette’s syndrome, attention-
deficit with hyperactivity disorder, and drug addiction, among others. Indeed, 
DA is inherently neurotoxic either by auto-oxidation or enzymatic 
metabolism. The generation of reactive oxygen species (ROS) from cytosolic 
DA, likely in combination with other factors such as mitochondrial 
dysfunction, α-synuclein aggregation, neuroinflammation, and impaired 
protein degradation lead to functional modifications in proteins, DNA and 
lipids. Lipid damage, in turn, compromises membrane integrity and increases 
permeability to ions like calcium (Ca2+), promoting excitotoxicity. Thus, 
VMAT2 is determinant in DA clearance and the reduction in its expression or 
its loss of function could adversely affect DA vesicular sequestration, a 
concomitant accumulation of cytosolic DA easily oxidizable and its depletion 
in the striatum, and development of a parkinsonian phenotype (Caudle et al., 
2007). 
 
1.2. PARKINSON’S DISEASE 
 
James Parkinson first described in his 1817 famous monograph ‘An 
essay for the Shaking Palsy’, some of the characteristics of the disorder 
named after him today. Parkinson described an apparent neurological illness 
based on just six individuals with a clear progressive motor disability 
(Parkinson, 1817; re-edition 2002). However, only in 1960, Ehringer and 
Hornykiewicz uncovered the signs of decreased DA concentration in the 
striatum of patients with PD (Ehringer and Hornykiewicz, 1962). This 
discovery enabled the first trials of L-DOPA in PD patients (Birkmayer and 
Hornykiewicz, 1998). More recently, some aspects contributing to death of 
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dopaminergic and non-dopaminergic cells in patients with PD have been 
identified, such as genetic mutations, anomalous processing of misfolded 
proteins by the ubiquitin-proteasome system (UPS) and the autophagy-
lysosomal mechanism, increased oxidative stress, mitochondrial dysfunction, 
inflammation and other processes (McNaught et al., 2001; Jankovic, 2008; 
Pan et al., 2008). 
Worldwide, this late-onset, slowly progressive synucleinopathy is the 
second most common neurodegenerative disorder after Alzheimer's disease 
and the most common movement disorder, affecting 1-2% of the population 
aged over 65 and nearly 5% by age 85 (Di Giovanni et al., 2010). 
 
 
  PATHOPHYSIOLOGY 1.2.1.
 
PD is characterized by severe motor disturbances, including resting 
tremor, postural instability, bradykinesia and progressive rigidity. Likewise, 
festinating gait, lack of facial expression, and eye blinking are often observed. 
The pathophysiological changes are extensive and marked by the death of 
neuromelanin-containing DA neurons in the SNpc, which results in a drastic 
reduction of dopaminergic projections to the striatum. Due to the major loss 
of striatal innervation, compensatory adjustments occur in DA dynamics, 
including increased DA synthesis and release in the remaining neurons, and 
up-regulation of postsynaptic DA receptors. However, in PD patients already 
exhibiting motor dysfunctions, these adaptations do not appear sufficient to 
counterbalance the loss of more than 50% of dopaminergic neurons 
projecting from the SNpc to the striatum and approximately 80% reduction in 
striatal DA levels (Fearnley and Lees, 1991). Moreover, additional neuronal 
systems are also affected, although less acutely, evidenced by degeneration of 
NE neurons of the locus coeruleus (LC), 5-HT neurons of the raphe nuclei, the 
dorsal motor nucleus of the vagus nerve, and the peripheral autonomic 
nervous system, among others (Lotharius and Brundin, 2002; Taylor et al., 
2009). 
Alongside the cardinal motor phenotype, there are non-motor 
symptoms that can appear years earlier and may be unnoticed or 
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misinterpreted for prolonged periods. These symptoms constitute the 
prodromal phase of PD, an important period that leads to early diagnosis, and 
typically includes hyposmia, GI dysfunction, anxiety, depressive and 
apathetic-like behaviour, and dysautonomia. Furthermore, nocturnal sleep 
disturbances are also common, affecting 60-98% of patients, and include 
night-time awakenings, sleep fragmentation, and REM sleep disorder. Some 
of these symptoms do not respond to dopaminergic therapies and profoundly 
impair the patients’ quality of life (Pfeiffer, 2003; Comella, 2007; Ziemssen 
and Reichmann, 2007). Still concerning the non-motor symptoms of PD, 
cognitive decline is detected at more advanced stages of the disease in a 
significant proportion of patients. 
 
 GENETIC BACKGROUND 1.2.2.
 
Approximately 5-10% of PD patients have monogenic forms of the 
disease, with either an autosomal dominant or autosomal recessive pattern of 
inheritance (Saito et al., 2000). The identification of genetic defects linked to 
PD is growing and at least 13 loci and 9 genes were confirmed to be related, 
among them: α-synuclein (SNCA), parkin (PRKN), probable cation-
transporting ATPase 13A2 (ATP13A2), leucine-rich repeat kinase 2 (LRRK2), 
PTEN-induced putative kinase 1 (PINK 1) and parkinson disease protein 7 or 
DJ-1, implying at least some genetic contribution in PD pathogenesis (Klein 
and Westenberger, 2012). These single gene defects are accountable for only a 
small number of PD cases, with the exception of LRRK2 gene which is the 
most representative cause of autosomal-dominant and sporadic forms of PD 
(Gilks et al., 2005). Until recently, there was only a small number of research 
reports looking into mitochondrial genetics and function in PD. Latest 
findings in PD brains and other tissues revealed abnormalities in complex 1 of 
the oxidative phosphorylation enzyme pathway, leading to cell dysfunction 
and death (Schapira, 2008). In addition, the investigations on single gene 
defects that are related to UPS, such as PRKN (an E3 ubiquitin ligase), have 
some potential to clarify the connection between PD and mitochondrial 
dysfunction. Furthermore, UPS failure leads to abnormal protein aggregation, 
including insoluble α-synuclein structures, which are the primary component 
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of Lewy bodies (LB) and Lewy neurites (Warner and Schapira, 2003; Betarbet 
et al., 2005), both histological hallmarks of PD. 
 
 HISTOLOGICAL MARKERS: LEWY BODIES  1.2.3.
 
LB are intracytoplasmic spherical inclusions composed of insoluble 
aggregates of α-synuclein, ubiquitin, amyloid precursor protein and amyloid-
beta peptides (Aβ), and represent the key feature for post-mortem assessment 
of PD. These structures are found in certain sites of neuronal loss, particularly 
the SNpc, but also the PFC, motor nucleus of the vagus nerve, hypothalamus, 
nucleus basalis of Meynert, LC and olfactory bulb (Forno, 1996). α-synuclein 
is a highly conserved presynaptic 140-amino acid phosphoprotein with 
chaperone-like structure. When present in high concentrations, monomeric 
α-synuclein can polymerize into filaments and fibrils, which can then form LB 
(Goedert, 2001). The presence of ubiquitin and other proteasomal subunits in 
LB suggests the involvement of α-synuclein and dysfunctional proteasomal 
degradation pathway in PD pathogenesis. Moreover, α-synuclein has been 
found to loosely bind and permeabilize monoaminergic vesicles, likely causing 
leakage of monoamines into the cytosol. In fact, Guo and colleagues identified 
a VMAT2-α-synuclein complex in which α-synuclein appears to down-
regulate the activity of VMAT2 in vitro, increasing cytosolic DA and ROS (Guo 
et al., 2007). 
 
 TERAPHY 1.2.4.
 
L-DOPA therapy started its revolution in the treatment of PD decades 
ago, and now DA replacement therapies in form of L-DOPA or DA agonist 
drugs are the standard therapeutics for PD patients. Even though it provides 
clear symptomatic relief to treated PD patients, improving daily living, 
employability and life span, it does not stop the progression of the disease. 
Despite of its effectiveness and suggestions of its protective and trophic 
effects, dopaminergic agents produce a scope of acute side effects resulting 
from activation of dopaminergic areas both in central and peripheral nervous 
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systems, including nausea, vomiting and hypotension.  It is well admitted that 
the dopaminergic denervation of the basal ganglia in PD is uneven and these 
side effects are due to overstimulation in the ventral striatum where 
dopaminergic innervation remains fairly intact (Voon and Fox, 2007). 
Another challenging point verse on when L-DOPA treatment should be 
initiated, in view of high prevalence of poorly understood motor 
complications such peak-dose, biphasic dyskinesia, paradoxical involuntary 
movements, and unpredictable motor fluctuations. Moreover, dopaminergic 
drugs decline their effect and efficacy as the disease progresses, comprising 
events such “wearing off” (the same dose of L-DOPA lasts for a shorter period 
of time with a decrease of the antiparkinsonian effect before the next dose) 
and “freezing” (sudden shifts between mobility and immobility) (Stocchi et 
al., 2008).  
Current pharmacologic interventions on motor symptoms of PD have 
also revealed the troublesome of treating simultaneously the diverse non-
motor components, which may occur before (eg, constipation), during (eg, 
excessive sweating), or after (eg, dementia) the onset of motor deficits. Non-
motor symptoms are only partially L-DOPA-responsive, and they remain 
largely refractory to existing interventions. The widespread neuronal loss that 
occurs in PD involving neurotransmitters other than DA may be the reason of 
the non-motor symptoms’ unclear pathophysiology (Chaudhuri et al., 2006).  
Such issues motivated the quest for other therapeutic approaches: 
studies on the neurorestorative effect of glial cell line-derived neurotrophic 
factor delivered into the nigrostriatal pathway, for instance, with promising 
signs of motor recovery in animal models of PD and PD patients (Saavedra et 
al., 2008); or technological interventions like electrical deep brain stimulation 
(DBS), considered the gold-standard therapy for PD nowadays. This 
technology relies on the implantation of chronic electrodes that modulate 
selected, focal basal ganglia structures, including the subthalamic nucleus and 
the globus pallidus, and it is advocated to patients developing the 
aforementioned motor complications to increasing amounts of medications 
required owing to progression of disease and worsening PD symptoms. The 
input of continuous electrical stimulation using brief >100 Hz pulses 
alleviates the same symptoms of PD that are relieved by L-DOPA therapy and 
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also reduces non-L-DOPA-responsive tremors with beneficial outcomes that 
exceed those achievable in comparable patients treated only with oral 
medication (Larson, 2014; Little and Brown, 2014). 
 
1.3. ANIMAL MODELS OF PD 
 
Mice, rats and nonhuman primates are the most broadly used animal 
models in PD studies. Briefly, injury or insults to DA-mediated pathways are 
replicated using a myriad of endogenous/exogenous toxins or genetic 
manipulations on these models. The ideal animal model exhibits a disease 
course of a few months or years during adulthood, with neuronal losses in the 
different dopaminergic brain areas exceeding 50%, clear motor disability that 
mimics PD, presence of LB, and, in case of a genetic manipulated models, a 
robust propagation of the mutation (Beal, 2001).  
The major toxin-induced models are achieved by administration of 
neurotoxin 6-hydroxydopamine (6-OHDA) or systemic administration of the 
neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Other less 
recurrent neurotoxin models involve administration of rotenone, paraquat, 
isoquinoline derivatives, or methamphetamine. Thus far, the dominance of 
motor-based animal models responsive to L-DOPA is solid. Although these 
models offer insight to possible causes of motor impairment, they fail to 
approach PD as a syndrome with complex extradopaminergic involvement 
and numerous non-motor features, and sometimes lack important hallmarks 
like the progressive nature of the pathology or LB occurrence (Langston, 
2006).  
The monogenic mutations seen in patients with familiar PD can be 
replicated in transgenic animal models, such as transgenic mice 
overexpressing normal or mutated human α-synuclein (Blesa et al., 2012). 
There are also models that attempt to genetically recreate the combination of 
destructive processes found in PD such as mitochondrial dysfunction, 
dysregulation of Ca2+ homeostasis, loss of trophic support or reduction of 
vesicular DA pool, which can be seen in mice with a drastic reduction of 
VMAT2 protein expression. 
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 VMAT2 LO MICE 1.3.1.
 
Several transgenic mouse lines with VMAT2 gene dysregulation have 
been generated. The complete deletion of the VMAT2 gene resulted in a weak 
animal with a lifespan of a few days after birth. This lethality provided 
evidence for the consequence of brutally reduced monoamine concentrations 
vital for monoaminergic signaling, as it has been seen in the past for TH 
knockout mice (Zhou et al., 1995). However, the mice that were heterozygous 
for VMAT2 displayed a 50% reduction in VMAT2 expression and were 
physiologically similar to the wild-type littermates, yet with a depressive-like 
phenotype. They did not display any motor signs of PD-like behaviour but 
manifested more marked deficits compared to wild-type animals when 
exposed with exogenous toxicants such as methamphetamine or MPTP 
(Takahashi et al., 1997). These susceptibilities showed that manipulating 
VMAT2 produced an increased sensitivity to PD-inducing toxins and 
demanded for a more profound disruption of the monoamine storage (Taylor 
et al., 2011). 
A line of mice expressing only 5% of the VMAT2 protein (VMAT2-
deficient, VMAT2 LO) was generated by Mooslehner and colleagues from the 
original colony at the Babraham Institute (Mooslehner et al., 2001). Briefly, 
the mouse VMAT2 locus was cloned from the 129/Sv genomic library and a 
2.2 kb PvuII fragment from the third intron of the VMAT2 gene, and then 
cloned into the blunt-ended NotI site of this construct. The targeting vector 
was introduced into 129/Ola CGR 8.8 embryonic stem cells and injected into 
blastocytes of C57BL/6 mice. Highly chimeric males were bred with C57BL/6 
females. Originally, the C57BL/6 inbred strain of mice contained a 
spontaneous chromosomal deletion spanning the α-synuclein gene locus, 
although all traces of that mutation got eliminated later by Caudle and 
colleagues (Caudle et al., 2007). 
VMAT2 LO mice are fully viable into adulthood and allow the study of 
reduced vesicular storage and poor monoaminergic innervation over an 
average lifespan of two years, among other PD-like features (Figure 1.4). They 
show severe reductions in DA, NE and 5-HT levels, increased oxidative stress, 
age-dependent loss of DA terminals and neurons in the SNpc/ VTA and 
 
     
 
13 
striatum with concomitant reduction in the metabolites DOPAC and HVA, 
and altered striatal neurotransmission and signaling, among others. 
Behaviourally, the VMAT2 LO exhibits several motor symptoms of PD which 
become progressively more severe with age, including reduced locomotor 
activity and impaired motor coordination (Taylor et al., 2011).  
 
 
Figure 1.4 – Timeline of parkinsonian features observed in the VMAT2 
LO mice mode from 2–30 months of age. Symptoms or pathology indicated by 
gradient colored box increased in severity as the mice aged. All boxes end at the last 
age the symptom or pathology was measured. (DAT: DA transporter; LC: locus 
coeruleus; SNpc: substantia nigra pars compacta; TH: tyrosine hydroxylase). 
Modified from Taylor and colleagues (Taylor et al., 2011). 
 
The study of VMAT2 LO mice revealed that a general disturbance of 
monoamine storage and handling is one of the keys to almost fully reproduce 
the symptoms associated with the disease. Hence, using this new model in 
new adjunct therapeutic strategies for PD can offer important complementary 
information about new approaches within DA replacement therapy. 
 
1.4. COMT INHIBITION 
 
L-DOPA treatment is the broadest therapy for PD. The optimal dosing 
schedule for each patient is crucial to reduce the expected motor 
Anxiety-like beh. Depressive behaviour 
Delayed gastric emptying 
Anosmia 
            Shortened sleep latency 
Reduced locomotor activity Shortened str. lenght 
α-synuclein accumulation 
   Loss of striatal DAT 
   LC degeneration 
SNpc degeneration 
Loss of striatal TH 
2 months 
30 months 
14 months old - start of 
the experiments 
18 months old - end 
of the experiments 
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complications. Changes in central pharmacokinetics underlie the 
development of L-DOPA-related motor fluctuations and dyskinesias, and the 
emergence of a L-DOPA ‘threshold’ for a response to the treatment. Increased 
doses of L-DOPA or smaller doses but administered more frequently may 
reduce these complications in the short-term but are not a durable solution 
(Stocchi et al., 2008). 
Only 5-10% of the oral dose of L-DOPA/benserazide administered to 
patients crosses the blood-brain barrier (BBB). The inhibition of the 
decarboxylation pathway by benserazide shifts the metabolism of L-DOPA to 
COMT metabolic pathway. Taken together, the inhibition of CNS COMT in 
combination with L-DOPA/benserazide therapy can be the answer to more 
continuous availability of L-DOPA in the CNS after each dose. Tolcapone 
(Tasmar®) and entacapone (Comtess®/Comtan®) are the two selective 
reversible inhibitors approved for PD treatment, however entacapone only 
acts peripherally, consistent with literature indicating a marked COMT 
inhibition by Tolcapone (Deane et al., 2004) (Figure 1.5).  
 
 
Figure 1.5 – Central and peripheral effects of COMT inhibition in L-DOPA 
metabolism. (3-OMD: 3-O-methyldopa; AADC: Amino acid decarboxylase; COMT: 
Catechol-O-methyltransferase; DOPAC: 3,4-Dioxyphenylacetic acid; HVA: 
L-DOPA 
L-DOPA 
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Homovanillic acid). Modified from Leegwater-Kim and Waters (Leegwater-Kim and 
Waters, 2006). 
 
Tolcapone (3,4-dihydroxy-4′-methyl-5-nitrobenzophenone) is a 
second-generation, highly selective, orally-active COMT inhibitor. It increases 
the plasma levels of L-DOPA 1.3 to 2.1-fold and prolongs its duration of action 
1.1 to 1.8-fold by reducing its metabolism to 3-OMD. 
The addition of the COMT inhibitor Tolcapone in fluctuating PD 
patients under L-DOPA regime showed indeed an improvement of motor 
scores and decrease in average L-DOPA daily dose. However, rare 
hepatotoxicity situations in Tolcapone-treated patients raised some concern 
after liver function tests showed abnormalities, especially among patients 
with moderate cirrhotic liver disease. Tolcapone has been associated with 
increased levels of serum glutamic pyruvic transaminase/alanine 
aminotransferase (ALT) and serum glutamic-oxaloacetic 
transaminase/aspartate aminotransferase (AST), whereby it should be used 
with caution and requires liver function monitoring. The mechanism 
underlying possible Tolcapone-induced liver damage may relate to 
abnormalities in mitochondrial respiration in hepatocytes due to uncoupling 
of oxidative phosphorylation (Borges, 2005). Other side-effects include new 
or worse dyskinesias, nausea and diarrhea, and sleep disturbances 
(Leegwater-Kim and Waters, 2006). 
The increase of 3-OMD by metabolism of L-DOPA via COMT is 
associated with conversion of SAM to SAH, and SAH is subsequently cleaved 
to homocysteine (Hcy) (Figure 1.6). In fact, hyperhomocysteinemia (HHcy) is 
seen in L-DOPA treated PD patients. Elevation in total Hcy (tHcy) is a 
suggested risk factor for stroke, coronary artery disease, and dementia beside 
others.  
In order to achieve a tHcy reduction, supplementation of vitamin B6 
(trans-sulfuration pathway) or vitamin B12 and folic acid (re-methylation 
pathway) are suggested on one hand and inhibition of COMT on a regular 
basis on the other. Since Tolcapone can cross the BBB, central COMT 
inhibition may hypothetically be neuroprotective in the long term, by 
reducing enduring degenerative changes and dementia associated with HHcy. 
Nevertheless, when COMT extensive detoxification role within the brain is 
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repressed, DA metabolism is forced to go further down to neurotoxic N-
methyl-4-phenylpyridine-like substrates, which brings unforeseen 
consequences (Müller and Kuhn, 2006). 
 
Figure 1.6 – Metabolism of L-DOPA to 3-OMD causes an increase in the 
formation of SAH, which is immediately metabolized to Hcy. (3-OMD: 3-
O-methyldopa; COMT: catechol-O-methyltransferase; Methylene THF: methylene 
tetrahydrofolate; MTHFR: methylenetetrahydrofolate reductase;  SAH: S-
adenosylhomocysteine; SAM: S-adenosylmethionine). Modified from Postuma and 
Lang (Postuma and Lang, 2004). 
 
 
1.5. AIM OF THE STUDY: INHIBITING COMT IN VMAT2 
LO MICE UNDER L-DOPA TREATMENT 
 
Altogether, we hypothesized Tolcapone to be effective as vascular and 
neuronal protector in PD, therefore improving functional outcome. Thus, as a 
novel concept, the aim of this study is to investigate the effect of COMT 
inhibition over behavioural, biochemical and histological outcomes in the 
context of PD in VMAT2 LO mice during the ‘off’ period of L-DOPA 
treatment. To achieve this, pharmacological inhibition of COMT with 
Tolcapone was performed in a VMAT2 LO and wild-type mice under L-
DOPA/benserazide treatment. Baseline and post-treatment changes in motor, 
olfactory and cognitive function were tested, as well as food intake, during 
periods without any treatment. Additionally, liver integrity was assessed by 
measuring the levels of ALT and AST. It is intended to also quantify tHcy 
levels in peripheral blood (to evaluate vascular protection) and 
immunohistochemical signs of neurodegeneration (to evaluate neuronal 
protection) at a later time point. 
L-DOPA 
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CHAPTER 2 
Materials and Methods 
 
 
2.1. STUDY DESIGN 
 
All experimental procedures were performed under the license n. ZH 
205/2012 and approved by both local and federal Swiss authorities. This 
study design was based on the availability of VMAT2 LO animals within the 
colony of the Animal Sleep Laboratory of the University Hospital of Zurich 
(USZ), and ran throughout February 2015 to mid-September 2015.  
The 119-day chronic experimental period began with one week of 
baseline behavioural testing and tail blood sampling followed by four more 
rounds of tests and blood collection (‘off’ period), spaced by three weeks of 
pharmacological treatment (‘on’ period). Oral administrations took place 
twice a day (8.00h or 9.00h, according to season, and 8 hours later). After the 
last round of tests, mice were euthanized, and brains and livers collected for 
posterior evaluations.  
In order to work with robust results, the behavioural data presented in 
this thesis only comprise the period between baseline and the end of the 2nd 
round, the so called sub-chronic window. This choice was made due to the low 
number of experimental subjects in the VMAT2 LO groups between 3rd and 
4th rounds, which are still running. However, the food intake test and 
quantification of plasma AST and ALT were performed during and after the 
4th round, respectively (Figure 2.1). 
 
Figure 2.1 – Chronologic representation of the experimental period, 
accounting all the treatment and behavioural testing weeks. The subjects 
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were not treated during weekends and during behavioural testing week, to avoid an 
acute effect of the pharmacologic interventions. 
 
 EXPERIMENTAL ANIMALS 2.1.1.
 
Male, adult C57BL/6J mice were used in all the experiments. VMAT2 
LO mice on a C57Bl/6 background were originally obtained from Jackson 
Laboratories and then bred in-house (BZL, USZ). Wild-type control C57BL/6 
mice were obtained from the group’s colony or ordered (Janvier Labs, Le 
Genest-Saint-Isle, France).  Male mice were used to avoid the influence of 
hormonal cycles on behaviour. Until the presentation of this thesis, the study 
comprised 43 mice, 24 wild-type and 19 VMAT2 LO, aged 14 months ± 18 
days on the first day of baseline behavioural testing.  
All animals were single housed in clear-transparent Euro-standard 
Type II L plastic cages (530 cm2 floor area, Indulab AG, Gams, Switzerland), 
containing autoclaved dust-free sawdust bedding, one cardboard mouse 
house (12 cm x 12 cm x 6 cm) and one facial tissue (20 cm x 20 cm) as nesting 
material. Tap water and regular chow (Provimi Kliba SA, Kaiseraugst, 
Switzerland) were provided ad libitum throughout the experiments. Both the 
stock and the experimental room were maintained on a 12 h light/dark cycle 
(lights on at 8.00h or 9.00h, according to season), and constant temperature 
(21 - 23 °C) and relative humidity (30%). All mice were weighed daily until 
completion of the studies. The animals had a period of acclimation to the 
room before all experimental procedures. 
 
 GENOTYPING AND PCR ANALYSIS 2.1.1.1.
 
All VMAT2 LO subjects were obtained from the group’s colony. These 
animals were permanently identified with ear punch numbering system, 
which can provide enough tissue for PCR screening. PCR analyses were made 
throughout the study using a PCR kit (DNeasy® Blood & Tissue Kit, Qiagen, 
Germany) to determine the genotype of the experimental animals. Genotypes 
were further confirmed from DNA extracted from tail samples taken 
immediately prior to the sacrifice of the animals.  
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Briefly, the PCR protocol was performed with the forward primer 
F330KA1 (5’-GCGAATATTCCAGTCCTCCA-3’) and the reverse primer KAR 
(5’- CAGGCAACACCAGAAACAAT-3’) for VMAT2 WT and RKA835 (5’- 
GGAAAGTGAGCCACCATGTAG-3’) for VMAT2 LO. Amplification was 
performed in a 25 µL reaction mixture with 9.5 µL nuclease free water, 1 µL 
forward primer (10 µM), 0.5 µL of each reverse primer (10 µM), 12.5 µL 
GoTaq green master mix (Promega, Madison, Wisconsin, USA) and 1 µL of 
DNA using a standard thermocycler (TProfessional; Biometra, Göttingen, 
Germany). PCR cycle started with 4 minutes of initial denaturation at 94°C, 
followed by 25 repeated cycles of 1 minute denaturation at 94°C, 1.5 minutes 
annealing at 57 °C and 1 minute of extension at 72 °C, and ended with 7 
minutes of final extension at 72 °C. PCR products were stained with GelRed 
(Biotium, Hayard, California, USA) separated with electrophoresis at 150 V 
for 1 hour in a 3% agarose gel (w/v) in 1x TAE buffer and visualized under UV 
light (Figure 2.2). 
 
Figure 2.2 – Confirmation of the PCR products by gel electrophoresis. 
The 3% agarose gel is visualized under UV light and the resultant bands are 
identified as VMAT2 wild-type, VMAT2 LO and VMAT2 heterozygous.  
 
 PHARMACOLOGIC TREATMENTS  2.1.2.
 
Mice were grouped into four treatment groups per genotype and 
distributed according to body weight and baseline tests’ performance, in order 
to certify balanced groups. The different treatments consisted of: saline 
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solution (NaCl 0.9% in water, 1 µL.kg-1, pH 7, Grosse Apotheke Dr. G., Bichsel 
AG, Switzerland) as placebo;  20 mg.kg-1 L-DOPA/benserazide (Madopar® 
125 mg, pH 6.1, Roche Pharma AG, Switzerland), 15 mg.kg-1 Tolcapone 
(Tasmar® 100 mg, pH 5.7, MEDA Pharma GmHB, Switzerland); and an 
equitable solution of 12.5 mg.kg-1 L-DOPA/benserazide and 15 mg.kg-1 
Tolcapone (Table 2.1). The concentration of drug in the L-DOPA/benserazide 
group represents the ordinary dosage (12.5 mg.kg-1) increased 1.6-fold, in 
order to mimic the bioavailability of DA on the groups treated with  
L-DOPA/benserazide + Tolcapone. 
 
Table 2.1 – Overview of the experimental groups. Groups’ distribution per 
genotype, doses administered in each one, and the number of animals in experiment 
and with the treatment complete until the final of the 2nd round of experiments. 
 
GROUP GENOTYPE 
LEVODOPA 
MADOPAR® 
TOLCAPONE 
TASMAR® 
TOTAL 
NUMBER OF 
ANIMALS IN 
EXPERIMENT 
NUMBER OF 
ANIMALS WITH 
TREATMENT 
COMPLETE UNTIL 
THE SECOND 
ROUND 
1 
VMAT2 WT 
NaCl  6 6 
2 20 mg.kg-1 - 6 6 
3 - 15  mg.kg-1 6 6 
4 12.5  mg.kg-1 15  mg.kg-1 6 6 
5 
VMAT2 LO 
NaCl  6 5 
6 20  mg.kg-1 - 5 4 
7 - 15  mg.kg-1 5 5 
8 12.5  mg.kg-1 15  mg.kg-1 6 5 
 
 
Drug suspensions were prepared no more than 3 days before each 
treatment week, aliquoted at -80 °C and administered at 0.5 – 1 mL.kg-1. 
During administration, drug vials were vigorously mixed to certify the 
homogeneity of the suspensions. All mice received 120 doses of the 
corresponding treatment throughout the 119 days experimental period. The 
doses were orally administered using a pipette 10 – 100 µL, and reported at 
the quality control as Good or Irregular. All mice under 50 g of body weight 
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received daily wet-food (50-75% water) ad libitum in addition to the regular 
chow. 
 
 BEHAVIOURAL TESTS 2.1.3.
 
All tests were performed during the light cycle, with room illuminance 
by white fluorescent lightbulbs of 90 lux. Prior and in between all training and 
testing trials, the behavioural apparatuses were cleaned with a mild, non-toxic 
water-based detergent (10% ethanol + 0.5% TEGOL).  
There were three behavioural tests to assess motor outcomes: open 
field test, rotarod test and bar test; and two to evaluate non-motor behaviour: 
olfactory discrimination test and novel object recognition test. All tests were 
conducted on three or four consecutive days, following the same order and at 
the same time of day.  
 
 OPEN FIELD TEST 2.1.3.1.
 
The open field test (Bello et al., 2011) is a common measure of 
exploratory behaviour in mice. This test was assayed to evaluate the 
spontaneous locomotor activity, namely the distance travelled, of VMAT2 WT 
and VMAT2 LO mice. 
The apparatus assembles 4 identical plexiglas boxes (46 cm x 46 cm x 
40 cm) and a video camera connected to an automated tracking system 
(EthoVision XT 9.0, Noldus, Germany) (Figure 2.3). Animals were habituated 
to the setup for 15 minutes on the day before the baseline testing. The actual 
test on the following day served as habituation for the non-motor tests on the 
subsequent days. Each trial had up to 4 animals simultaneously which were 
allowed to explore the arenas freely for 30 minutes. In this test, the total 
distance traveled (in centimeters) was the output parameter, which was 
plotted by treatment group and over time. 
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Figure 2.3 – Top view of the open field apparatus. Four plexiglas adjacent 
boxes are separated with wood dividers to avoid animals’ eye contact, and placed 
over an infrared light. A ceiling hanging infrared camera captures the movements of 
the multiple subjects and sends the data to a PC for storage and analysis.  
 
 ROTAROD TEST 2.1.3.2.
 
To assess the motor coordination in VMAT2 WT and VMAT2 LO mice, 
a rotarod test was carried out (Avale et al., 2003).  
A standard mouse rotarod machine with a horizontally oriented, 
rotating cylinder, integrated timers and falling sensitive platforms 
(UgoBasile©) was set to constant 16 revolutions per minute and could 
accommodate 5 mice simultaneously (Figure 2.4). A 10-minutes training 
session was assayed 3 hours before the test. During this training, mice were 
repeatedly repositioned on the rod after each fall, in order to maximize the 
learning period. During the testing phase, the animals were placed onto the 
rotating treadmill until a maximum time of 180 seconds. A second chance was 
given for those who fell meanwhile. The higher latency to fall (in seconds) 
extracted from both attempts was considered for the analysis, and plotted by 
treatment group and round of experiments. 
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Figure 2.4 – Front view of the rotarod machine (UgoBasile©). The 
equipment has a horizontally oriented, rotating cylinder 15 cm high, integrated 
timers and falling sensitive platforms that can accommodate 5 mice simultaneously, 
facing a wide black curtain. 
 
 BAR TEST 2.1.3.3.
 
The bar test (Noain et al., 2013) was conducted to examine the body 
rigidity or catalepsy related to impaired dopaminergic neurotransmission in 
the nigrostriatal pathway. 
The animals were placed sitting on the working table over their hind 
paws and grabbing a 4 cm elevated acrylic bar (1 cm diameter) with their front 
paws (Figure 2.5). Immediately after, the timer was started. A trial was 
considered valid when the animal remained grabbing the bar with the front 
paws at least 1-2 seconds (until the timer was running). Usually, 1-3 trials 
were invalid for each mouse at the beginning of the testing session. The time 
of immobility was counted in 5 trials with a 180 seconds cutoff for each trial. 
For the analysis, a trimmed mean was calculated discarding the lowest and 
the highest time values for each mouse over the 5 trials and the results were 
plotted by treatment group and round of experiments. 
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Figure 2.5 – Bar test apparatus. The 4 cm elevated acrylic bar and both plastic 
bases were fixed to the surface with white tape. The test is done facing a wide black 
curtain. 
 
 OLFACTORY DISCRIMINATION TEST 2.1.3.4.
 
The olfactory discrimination test was applied in the study as a test 
control for non-responsiveness to L-DOPA/benserazide plus Tolcapone 
therapy, as it is known that DA replacement therapy has no effect over this 
phenotype (Taylor et al., 2011). 
The experiments were adapted from Taylor and colleagues (Taylor et 
al., 2009). Two 100% cotton odorless discs (~6 cm diameter) were placed into 
labeled falcon tubes containing bedding from each test animal’s cage for at 
least 12 hours. During the test, the mouse was presented with one cotton disc 
scented with its own bedding and a cotton disc scented with another mouse’s 
bedding (Figure 2.6). Along all the rounds of experiments, the positions of the 
discs were alternated, to avoid place preferences. Sniffing was defined when 
the animal’s nose was located within a zone 2 cm or less from each disc. The 
cumulative time spent within both these zones was recorded during a 2-
minutes trial starting from the moment the nose point was detected inside 
any of the aforesaid zones. For the analysis, the recognition index was 
calculated as the cumulative time spent sniffing the disc scented with a 
foreign animal’s bedding divided by the total cumulative time spent sniffing 
both discs and presented by treatment group and round of experiments. 
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Figure 2.6 – View of the open field with cotton discs for the olfactory 
discrimination test. The discs were fixed to the base always in the same side of the 
arena and the mouse is placed on the other side, in the middle, facing the discs. 
 
 NOVEL OBJECT RECOGNITION TEST 2.1.3.5.
 
The novel object recognition test was performed in the interest of 
evaluate the effect of Tolcapone treatments on episodic memory (Büchele et 
al, 2015). 
The novel object recognition test consisted of a training phase followed 
by a testing phase 3 hours later. During the training phase, two identical small 
objects were placed in both corners of one side of the open field. Mice were 
placed in the opposite side facing the objects (Figure 2.7) and left free to 
explore during 5 minutes. During the testing phase, one object was replaced 
by a novel one, different in colour, shape and texture. The animals were 
placed again in the opposite side facing the objects and left to explore for 3 
minutes. Here, the position of the new object was also alternated with the 
familiar counterpart over all the rounds of experiments, to avoid side 
preferences. An approach was considered valid every time the nose-point 
could be detected inside an area of 2 cm from the limits of that same object. 
The cumulative time spent exploring each object was recorded. Since the 
novelty factor is crucial in this test, the objects were not repeated for the same 
animal throughout all the experiments. However, the objects were saturated 
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with smelling cues due to reuses over the years, which required a vigorous 
cleanliness with 70% ethanol solution before and after every training and 
testing trial. Moreover, the animals that did not show any exploratory interest 
for any of the objects during the testing phase, performed again on the same 
day, with a new set of objects. For the analysis, the recognition index was 
calculated as the cumulative time spent inside the novel object zone divided 
by the total cumulative time spent inside both zones and plotted by treatment 
group and round of experiments. 
Figure 2.7 – View of the open field with two different objects for a novel 
object recognition trial. The objects were fixed to the base of the arena and the 
mouse is placed on the other side, in the middle, facing the objects. 
 
 FOOD INTAKE 2.1.4.
 
VMAT2 LO mice show a clear distinct body complexion compared to 
wild-type mice since birth. They require a period of up to 1 month with the 
progenitors until weaning (instead of the standard 21 days), a special feeding-
program afterwards and their littermates company. Visually, they are smaller 
and less vigorous, but the relation of these features with the feeding behaviour 
is unclear. Since there is no information about this aspect, the chance of 
characterizing food intake in VMAT2 LO mice was taken, together with the 
analysis of the different treatments’ influence on the subjects’ feeding 
behaviour. 
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Between the 99th and the 103rd day of treatment, all the dry food was 
removed from the cages and every mouse was presented only with a cup (𝑤 = 
2.37±0.005 g) containing wet food (74±0.5% water). Each mouse received at 
17.00h between 30-60 g of wet food (𝑥𝑖), prepared 24 hours earlier. There 
were also prepared 8 labeled control cups, with 10-70 g portions, placed in 
empty cages in the stockroom, intended to determine the percentage of 
weight lost by overnight water evaporation 𝐸1  (17.00h - 9.00h) and 
percentage of weight lost by water evaporation during day 𝐸2 (9.00h - 17.00h) 
as a function of total weight of the cup. At 9.00h and at 17.00h, the test and 
control cups were weighed (𝑥𝑖𝑖 and 𝑥𝑖𝑖𝑖, respectively).  
To calculate the food intake  𝑓𝑡𝑜𝑡𝑎𝑙  in g.24h-1, based on visual 
observations showing that mice start eating not long after the wet food is 
offered and excluding the water of the eaten portion, the following formula 
was applied: 
𝑓𝑡𝑜𝑡𝑎𝑙 =  0.26 ∙ [(𝑥𝑖 − 𝑥𝑖𝑖) − 𝐸1(𝑥𝑖) ∙ (𝑥𝑖𝑖 − 𝑤)] + 𝛼 ∙ [(𝑥𝑖𝑖 − 𝑥𝑖𝑖𝑖) − 𝐸2(𝑥𝑖𝑖) ∙ (𝑥𝑖𝑖𝑖 − 𝑤)] 
with 𝛼 = 0.26 + 0.74 ∙ [𝐸1(𝑥𝑖) + 𝐸2(𝑥𝑖𝑖)] 
The results were plotted by genotype. 
 
 BLOOD COLLECTION FOR DETERMINATION OF 2.1.5.
THCY AND LIVER ENZYMES 
 
In order to avoid stress-related outcomes, blood collections took place 
between 7-9 days after the last treatment day of each round, after the 
behavioural testing phase. No more than 10% of total circulating blood 
volume was collected, without anesthesia, from tail vein into lithium-heparin 
coated tubes (Microtainer®, BD, Switzerland). Some mice did not undergo 
blood sampling because they were too big for the restrainer (Figure 2.8). At 
the final timepoint, <600 µL of blood was taken directly from the right atrium 
immediately before the perfusion procedure.  
The metabolites of interest were tHcy and the liver enzymes AST and 
ALT. tHcy levels were intended to be analyzed at baseline, between 2nd and 3rd 
rounds, and at final endpoint from blood samples of all subjects at the 
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research laboratory of the neurology department (USZ) using an absorbance 
kit (Mouse Homocysteine Kit, Crystal Chem, The Netherlands). The liver 
enzymes were examined in the samples from the final endpoint from the 
VMAT2 WT control and VMAT2 WT L-DOPA/benserazide + Tolcapone 
groups at the Institute for Clinical Chemistry (USZ). 
 
Figure 2.8: Materials for blood sampling. The blood is collected with a 1 mL 
insulin syringe and transferred to a lithium-heparin coated tube. 
 
 PERFUSION AND TISSUE PRESERVATION 2.1.6.
 
Mice were sacrificed by classic full-body transcardiac perfusion. 
Briefly, subjects were anesthetized with sodium pentobarbital (50 mg.kg-1, 
i.p.). After fixation and chest opening, the liver was visually evaluated and 
photographed, the heart right atrium was incised and blood collected to a 
lithium heparin gel coated tube (Figure 2.9).  
 
 
 
 
 
Figure 2.9: Schematic procedure of full-body transcardiac perfusion in 
mice. The anesthetized mouse is fixed to the working platform and the chest is open. 
The right atrium of the heart is perforated (with collection of the blood) and the 
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exsanguination was performed by intracardiac perfusion into the left ventricle of the 
heart. Modified from Gage and colleagues (Gage et al., 2012). 
 
Complete exsanguination was performed by intracardiac perfusion of 
ice-cold phosphate–buffered saline (PBS) into the left ventricle of the hearth. 
The animal was fixed by subsequent perfusion of 4% paraformaldehyde (PFA) 
in PBS. Afterwards, the liver and the brain were immediately removed, post-
fixed and cryoprotected by dehydration in a 4% PFA/ 15% sucrose in PBS 
solution, at 4 ℃ for 12h, to avoid freezing effect during cryosectioning. A 
following step of dehydration in 30% sucrose in PBS occurred at 4 ℃ for 24h. 
Finally, the organs were placed in cryomolds, frozen in 30% sucrose in PBS 
solution and stored at -20 ℃ until further use. 
 
2.2. STATISTICAL ANALYSIS 
 
In all experiments, data are presented as means ± SEM. Repeated-
measures ANOVA with nested factors followed by Bonferroni post hoc 
analysis, one-way ANOVA, unpaired Student's t-test two-tailed and one 
sample t-test were applied as appropriate using IBM SPSS Statistics 22.0.0.1 
and GraphPad Prism 5.0.4 for Windows. A value of p<0,05 was considered 
statistically significant. 
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CHAPTER 3 
Results 
 
 
As previous mentioned, the results presented in this thesis are only 
concerning the baseline, 1st and 2nd rounds for the sake of group power. 
However, quantifications of food intake and blood markers of liver damage 
were assessed at the last round and are also shown here. 
The rate of successfull doses administration throughout the study 
stands very high, with only 2.53% of them being Irregular. 
 
3.1. AGE, BASELINE BODY WEIGHT AND BODY WEIGH 
PROGRESSION OF VMAT2 WT AND VMAT2 LO MICE 
 
Mice around 14 months of age at baseline were included in this study 
(Figure 3.1A). They were distributed within the batches and the treatment 
groups in a way that minimized the age variability between groups. The mice 
were weighted every weekday throughout the experiments. In order to 
……………………….…. 
 
Figure 3.1: VMAT2 LO mice display a significantly low body weight at 14 
months of age and similar weight increment. A, distribution of all subjects’ 
ages at the 1st day of experiments (n=43). B, VMAT2 LO mice show a significantly 
reduced body weight at 14 months of age compared to VMAT2 WT. Results represent 
the mean of body weight of all subjects (g) ± SEM per genotype (VMAT2 WT=24, 
VMAT2 LO=19, **p<0,01). C, Weight increment on both genotypes at the end of 2nd 
round is similar (VMAT2 WT=24, VMAT2 LO=19). Results represent the mean 
increment in body weight (% of body weight at baseline) ± SEM per genotype.  
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characterize the VMAT2 LO mice concerning their body weight, all measures 
from baseline were confronted. The VMAT2 LO mice show a significant lower 
body weight compared to VMAT2 WT mice (unpaired t-test two-tailed, 
**p<0,01; Figure 3.1B). The weight increment was also evaluated 56 days 
after baseline, i.e. until the end of the 2nd round. The weight increment 
analysis shows no significant differences between the treatment groups in 
either genotype (data not shown). Moreover, the weight increment of VMAT2 
LO mice is similar to the VMAT2 WT controls (unpaired t-test two-tailed, 
p>0,05; Figure 3.1C).  
 
3.2. FEEDING BEHAVIOUR 
 
The food intake of the mutant line was evaluated between the 99th and 
the 103rd days of treatment. Since all subjects were on a wet-food diet 
(74±0.5% water), an established procedure was used so that the consumption 
of actual chow could be extracted from each measurement, minimizing the 
inaccuracy of the test. The data was merged into genotypes, as the treatments 
show no effect on the feeding behaviour of the animals (data not shown). 
Although the subjects of both genotypes consume the same amount of food 
per day (unpaired t-test two-tailed, p>0,05; Figure 3.2A), the results show a 
significant increase of the food intake in relation to body weight in VMAT2 LO 
compared to VMAT2 WT (unpaired t-test two-tailed, *p<0,05; Figure 3.2B). 
 
Figure 3.2: VMAT2 LO mice eat significantly more than VMAT2 WT mice 
in relation to their own body weight, despite of both genotypes have 
shown similar food consumption. A, VMAT2 WT and VMAT2 LO mice show a 
similar result regarding the mean amount of eaten chow (g) ± SEM per genotype per 
day (VMAT2 WT=23, VMAT2 LO=9). B, VMAT2 LO mice reveal an exacerbated food 
intake compared to VMAT2 WT subjects. Results represent the mean food intake (% 
of body weight) ± SEM per genotype per day (VMAT2 WT=23, VMAT2 LO=9, 
*p<0,05). 
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3.3. BEHAVIOURAL TESTS 
 
 LOCOMOTOR ACTIVITY 3.3.1.
 
The open field test (Bello et al., 2011) was performed to evaluate the 
effect of Tolcapone treatments on the spontaneous locomotor behaviour of 
VMAT2 WT and VMAT2 LO mice under L-DOPA treatment.  
 The results show a significant difference at baseline between VMAT2 
WT and VMAT2 LO mice (unpaired t-test two-tailed, ***p<0,001; Figure 
3.3A), with a marked hypolocomotion in the mutant group. However, no 
major differences are seen between the treatment groups within each 
genotype after the 1st and 2nd rounds of testing (repeated measures ANOVA 
with nested factors, p>0,05; Figure 3.3B and 3.3C, respectively). 
 
Figure 3.3: VMAT2 LO mice exhibit hypolocomotor activity at baseline 
and do not respond to pharmacological interventions. A, VMAT2 LO mice 
show a substantial reduction in distance travelled at 14 months of age compared to 
WT controls. Results represent the mean distanced moved (cm / 30 min) ± SEM per 
genotype (VMAT2 WT=24, VMAT2 LO=19, ***p<0,001). The treatments did not 
show a significant effect in either genotype at 1st (B) and 2nd (C) rounds. Results 
represent the mean distanced moved (cm / 30 min) ± SEM per treatment group 
(VMAT2 WT: Vehicle=6, L-DOPA=6, Tolcapone=6, L-DOPA + Tolcapone=6; 
VMAT2 LO: Vehicle=5, L-DOPA=4, Tolcapone=5, L-DOPA + Tolcapone=5). 
 
 
The results show a significant negative progression of exploratory 
behaviour in all VMAT2 WT groups due to habituation effect from baseline to 
1st and 2nd rounds. The VMAT2 LO treated with saline is the only group of the 
mutant line that experiences this affect, while the remaining groups of 
VMAT2 LO show no contextual memory formation (repeated measures 
ANOVA with nested factors, *p<0,05; **p<0,01; ***p<0,001; Figure 3.4). 
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Figure 3.4: The habituation effect over time in VMAT2 LO and VMAT2 
WT controls. VMAT2 WT mice of all treatment groups show a substantial 
reduction in distance travelled throughout the study while VMAT2 LO of the vehicle 
group are the only ones that appear to form a contextual memory. Results represent 
the mean distanced moved (cm / 30 min) ± SEM for A, vehicle groups (VMAT2 
WT=6, VMAT2 LO=5), B, L-DOPA groups (VMAT2 WT=6, VMAT2 LO=4); C, 
Tolcapone groups (VMAT2 WT=6,  VMAT2 LO=5); D, L-DOPA + Tolcapone groups 
(VMAT2 WT=6, VMAT2 LO=5); *p<0,05; **p<0,01; ***p<0,001. 
 
 
 MOTOR COORDINATION 3.3.2.
 
 
To evaluate the effect of Tolcapone treatments over motor coordination 
in VMAT2 LO mice and their VMAT2 WT controls, a rotarod test (Avale et al., 
2003) was carried out as described earlier.  
At 14 months of age, the motor coordination of VMAT2 LO mice is 
considerably reduced as compared to their VMAT2 WT controls (unpaired t-
test two-tailed, ***p<0,001; Figure 3.5A). The treatments show the absence of 
a consolidated or significant effect on both genotypes at 1st and 2nd rounds of 
testing (repeated measures ANOVA with nested factors, p>0,05; Figure 3.5B 
and 3.5C, respectively). 
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Figure 3.5: VMAT2 LO mice display weaker motor coordination at 
baseline and do not respond significantly to the interventions at 1st and 
2nd rounds. A, VMAT2 LO mice show a severe motor disturbance by low individual 
times onto the rotating rod at 14 months of age. Results represent the mean latency 
to fall (s) ± SEM per genotype (VMAT2 WT=24, VMAT2 LO=19, ***p<0,001). B and 
C, The treatments did not show a significant change in any of the groups at 1st and 2nd 
round, respectively. Results represent the mean latency to fall (s) ± SEM per 
treatment group (VMAT2 WT: Vehicle=6, L-DOPA=6, Tolcapone=6, L-DOPA + 
Tolcapone=6; VMAT2 LO: Vehicle=5, L-DOPA=4, Tolcapone=5, L-DOPA + 
Tolcapone=5). 
 
 
The time progression on each treatment and genotype shows no 
significant differences but some tendencies can be depicted, especially the 
worsening of VMAT2 LO mice treated with vehicle (repeated measures 
ANOVA with nested factors, p>0,05; Figure 3.6A) and the relative 
amelioration of VMAT2 LO mice treated with L-DOPA + Tolcapone (repeated 
measures ANOVA with nested factors, p>0,05; Figure 3.6D). 
 
Figure 3.6: The treatments show no significant effect on motor 
coordination in either genotype over time. VMAT2 WT and VMAT2 LO high 
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variability can be seen in all the treatments. Results represent the mean latency to 
fall (s) ± SEM for A, vehicle groups (VMAT2 WT=6, VMAT2 LO=5); B, L-DOPA 
groups (VMAT2 WT=6, VMAT2 LO=4); C, Tolcapone groups (VMAT2 WT=6, 
VMAT2 LO=5); D, L-DOPA + Tolcapone groups (VMAT2 WT=6, VMAT2 LO=5). 
 
 
 RIGIDITY OR CATALEPSY 3.3.3.
 
In order to determine the effect of Tolcapone treatments over body 
rigidity or catalepsy, a bar test (Noain et al., 2013) was conducted as 
previously described.  
The VMAT2 LO mice show a significantly increased spontaneous 
rigidity at 14 months of age when compared to VMAT2 WT mice (unpaired t-
test two-tailed, ***p<0,001; Figure 3.7A). The phenotypes of either group did 
not effectively change with the treatments neither at 1st and 2nd rounds of 
testing (repeated measures ANOVA with nested factors, p>0,05; Figure 3.7B 
and 3.7C, respectively). 
 
Figure 3.7: VMAT2 LO mice display increased spontaneous rigidity at 
baseline and do not respond to the interventions at 1st and 2nd rounds. A, 
VMAT2 LO mice are immobile for longer periods of time in the bar test at 14 months 
of age. Results represent the mean time of immobility (s) ± SEM per genotype 
(VMAT2 WT=24, VMAT2 LO=19, ***p<0,001). B and C, The treatments did not 
have an effect in any of the groups at 1st and 2nd round, respectively. Results 
represent the mean time of immobility (s) ± SEM per treatment group (VMAT2 WT: 
Vehicle=6, L-DOPA=6, Tolcapone=6, L-DOPA + Tolcapone=6; VMAT2 LO: 
Vehicle=5, L-DOPA=4, Tolcapone=5, L-DOPA + Tolcapone=5). 
 
 
The evaluation of treatments over time show a significant response in 
the VMAT2 LO on the L-DOPA + Tolcapone groups between baseline and 2nd 
round (repeated measures ANOVA with nested factors, *p<0,05; Figure 
3.8D). A tendency towards worsening of VMAT2 LO mice treated with vehicle 
can also be appreciated (repeated measures ANOVA with nested factors, 
p>0,05; Figure 3.8A). 
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Figure 3.8: The treatments show no significant differences in immobility 
time in either genotype over time, except in the L-DOPA + Tolcapone 
group. VMAT2 LO high variability is found in this test in all the treatments. Results 
represent the mean latency to fall (s) ± SEM for A, vehicle groups (VMAT2 WT=6, 
VMAT2 LO=5); B, L-DOPA groups (VMAT2 WT=6, VMAT2 LO=4); C, Tolcapone 
groups (VMAT2 WT=6, VMAT2 LO=5); D, L-DOPA + Tolcapone groups (VMAT2 
WT=6, VMAT2 LO=5, *p<0,05). 
 
 OLFACTORY FUNCTION AND EPISODIC MEMORY 3.3.4.
ASSESSMENT 
 
To test the effect of Tolcapone treatments on olfactory function, an 
olfactory discrimination test was performed. This test is known not to 
respond to DA replacement therapy per se, thus it was used to evidence the 
effect of Tolcapone treatment itself (Taylor et al., 2011). 
The results show no significant differences at baseline, however the 
dispersion of the recognition scores is higher in VMAT2 LO mice as compared 
to VMAT2 WT (unpaired t-test two-tailed and one sample t-test (to 50%), 
p>0,05; Figure 3.9A). Thus, the analysis of treatment effects over unchanged 
olfactory discrimination becomes irrelevant and is not presented in this 
thesis. 
The novel object recognition test was performed to evaluate the effect 
of Tolcapone treatments on episodic memory (Büchele et al, 2015). 
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The results did not show any differences between genotypes at baseline 
(unpaired t-test two-tailed and one sample t-test (to 50%), p>0,05; Figure 
3.9B). As before, the analysis of treatment effects over unchanged memory 
ability becomes irrelevant and is not presented in this thesis. 
 
Figure 3.9: VMAT2 WT and VMAT2 LO mice do not display significant 
differences in olfactory discrimination and novel object recognition at 14 
months of age. A, The olfactory discrimination scores of VMAT2 WT and VMAT2 
LO mice are not significantly different at 14 months of age. Results represent the 
mean recognition index (time the animal spent exploring the disc scented with 
foreign animal’s bedding  divided per total time the animal spent exploring both 
discs) ± SEM per genotype (VMAT2 WT=24, VMAT2 LO=18). B, VMAT2 WT and 
VMAT2 LO mice behave similarly in novel object recognition test at 14 months of 
age. Results represent the mean recognition index (time the animal spent exploring 
the novel object divided per total time the animal spent exploring both objects) ± 
SEM per genotype (VMAT2 WT=21, VMAT2 LO=17). 
 
3.4. QUANTIFICATION OF THCY, ALT AND AST LEVELS 
 
We aim at assessing the tHcy levels in regular blood collections before 
and after the treatment with Tolcapone, to verify its protective effect on HHcy 
found in PD patients (Müller and Muhlack, 2009). This analysis will take 
place in the near future, after all blood samples have been collected and 
processed.  
Since Tolcapone is associated with rare cases of liver damage, the 
plasma levels of AST and ALT were quantified in VMAT2 WT group treated 
with vehicle and VMAT2 WT group treated with L-DOPA + Tolcapone, at the 
end of the 4th round of experiments (unpaired t-test two-tailed, p>0,05; 
Figure 3.10A and 3.10B, respectively). Despite of being slightly decreased on 
both genotypes comparing to 12 months aged mice (Mazzaccara et al., 2008), 
the AST/ALT ratio is found to be within standard levels on both genotypes 
(unpaired t-test two-tailed, p>0,05; Figure 3.10C). 
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The visual evaluation of the liver at the time of sacrifice and perfusion 
did not reveal any obvious structural damage (photographic data not shown). 
 
Figure 3.10: Plasma levels of AST and ALT do not show signs of 
hepatotoxicity related to Tolcapone chronic administration. Plasma levels 
of AST (A) and ALT (B) in U/L are within expected levels. Results represent the 
mean of plasma enzyme ± SEM (VMAT2 WT: Vehicle=4; L-DOPA + Tolcapone=3) C, 
AST/ALT ratio is marginally increased in the VMAT2 WT group treated with L-
DOPA + Tolcapone, yet not reaching concerning levels. Results represent the mean 
of individual AST/ALT ratios ± SEM (VMAT2 WT vehicle=4, VMAT2 WT L-DOPA + 
Tolcapone=3). 
  
  
 
40 
  
 
     
 
41 
CHAPTER 4 
DISCUSSION AND CONCLUSIONS 
 
 
Parkinson’s disease is a common neurodegenerative disorder afflicting 
1-2% of the population aged over 65 and nearly 5% by age 85 (Di Giovanni et 
al., 2010). With an ageing population, the management of PD is a challenge in 
clinical practice and research. New mouse models that attempt to fully 
represent PD are being developed and many of them reproduce, indeed, the 
complex collection of motor and non-motor features. Regarding the 
therapeutics, DA replacement stands as the standard treatment for PD 
although it underlies several complications in the long-term (Stocchi et al., 
2008). COMT inhibitors such as Tolcapone have been studied for its efficacy 
in PD as an adjunctive treatment to L-DOPA, reducing ‘off’ episodes and 
possible attenuating the mechanisms linked to vascular events and 
neurodegeneration (Müller and Muhlack, 2009). In this study, we 
characterize the motor behaviour of a mouse model of PD with 95% reduced 
expression of normal VMAT2 protein under L-DOPA and Tolcapone 
treatment, and attest whether Tolcapone intrinsically acts as autonomous 
motor ameliorator and vascular and neuronal protector at long term or 
depends on concomitant use of exogenous L-DOPA in the context of PD.   
In order to explore the effects of Tolcapone in motor and non-motor 
symptoms of PD in VMAT2 LO mice under sub-chronic L-DOPA treatment, 
an appropriate battery of behavioural tests was designed, including tests 
responsive and non-responsive to L-DOPA. To distinguish whether Tolcapone 
had an independent effect on motor features of PD, open field test, rotarod 
test and bar test were assayed during the ‘off’ periods. Moreover, the olfactory 
discrimination and the novel object recognition tests were performed in the 
same conditions in order to measure a possible response only linked to 
Tolcapone in non-motor symptoms either responsive or non-responsive to L-
DOPA, respectively. 
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  The motor disabilities in aged VMAT2 LO mice were well 
characterized by Taylor and colleagues (Taylor et al., 2009). This model 
displays decreased locomotor behaviour, impaired motor coordination and 
increased spontaneous rigidity, like our motor tests’ results at baseline 
corroborate. Furthermore, VMAT2 LO have been shown to present increased 
locomotor activity after acute L-DOPA treatment (Caudle at al., 2007). 
However, both genotypes do not seem to respond to sub-chronic L-DOPA, 
Tolcapone or L-DOPA + Tolcapone interventions, with the exception of 
rigidity or catalepsy, which show amelioration in mutant mice at 14 months 
old. It is well known that neither L-DOPA nor Tolcapone have a build-up 
effect that could maintain increased levels of DA during the ‘off’ period 
(Gershanik, 2015). Given that our sub-chronic treatments were interrupted 
during the testing week, the lack of acute effect of DA replacement was 
expected. On the other hand, the novel result presented in this thesis is that 
no disease modifying effect was observed by inhibiting COMT, nor alone or in 
combination with DA replacement, disregarding rigidity or catalepsy as 
aforementioned, which suggests some positive influence of COMT inhibition 
on this symptom’s progression.   
In the open field test, it is worth to note that all VMAT LO treated 
groups, except for the vehicle one, seem unable to form a contextual memory 
–i.e. they lack the expected habituation-to-context effect–, suggesting that the 
treatments have had a negative impact on memory formation or recall. 
Further studies would be needed to determine the nature of such observation 
and explore in more detail possible cognitive disabilities in VMAT2 LO mice. 
Concerning motor coordination and rigidity, our results show a trend towards 
a positive effect of L-DOPA therapy, however, animals in the group treated 
with Tolcapone alone appear not to follow a similar trend. Moreover, it is 
worth to note the significant impact of L-DOPA + Tolcapone over body 
rigidity in mutant mice 2 months after the beginning of the treatment. 
Following studies are needed in these matters. 
The non-motor tests assayed in this study show no differences between 
VMAT2 WT and VMAT LO at baseline. These negative results may relate to 
several limitations: a) the reduced size of the experimental groups, which may 
have taken power to these results; b) both tests were very susceptible to 
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changes in the environmental conditions such as noise and smells, among 
others, which may have hampered their sensitivity to detect subtle 
behavioural changes; c) the decreased exploratory behaviour of the VMAT2 
LO mice is preponderant in such short trials, evidenced by several subjects 
not performing the test at all; d) the shift between the age of the mice tested 
in this study and the actual age when the non-motor disturbances are greater, 
specially dementia; and finally, e) the high number of VMAT2 LO different 
batches over time that were needed to complete the group numbers, which 
may have had an impact on the variability of the test results.  
On the last round of experiments, the feeding behaviour was assessed 
in order to know whether the significant difference in body weight between 
genotypes in baseline were due to reduced food intake, owed to damaged 
reward pathway, or dwarfism, as it has been described in the past for other 
DA neurotransmission impaired models (Diaz Torga, et al., 2002; Noain et 
al., 2013). The pharmacologic interventions had no significant effect on body 
weight progression on both genotypes, but our results suggest that VMAT2 
LO mice ingest more than VMAT2 WT ones in relation to their body weight 
and independently of the treatments. This observation may be linked to a 
strategy of the mutant animals to compensate for their smaller body weight, 
or others so far undescribed pathological changes (reduced body temperature, 
increased metabolism perhaps, etc.). In addition, the power of the VMAT2 LO 
groups is relatively low. Further analyses with additional data are necessary to 
confirm these claims. However, our results so far suggest that VMAT2 LO 
mice have a similar or even increased food intake as compared to their WT 
controls. Thus, dwarfism becomes a possible explanation for the observed 
reduced body weight. In detail, hormonal profiling would be needed in order 
to actually determine a dwarf phenotype in these mice, including 
determinations of growth hormone among others (Noain et al., 2013). 
In regard to the blood markers of hepatotoxicity, which could arise 
from the heavy drug load over the period of treatment, especially in the 
groups administrated with Tolcapone, our results show a minor and not 
significant influence on liver functions between VMAT2 WT untreated and 
treated with L-DOPA + Tolcapone groups. Further studies on plasma tHcy at 
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the final endpoint of the pharmacological intervention are planned for the 
near future.      
Overall, our preliminary results suggest that sub-chronic COMT 
inhibition per se or in combination with DA replacement treatment has no or 
little beneficial effect over motor outcomes in the context of PD. Completion 
of the 3rd and 4th rounds of testing is needed to appreciate the effect of chronic 
exposure to the treatment. Furthermore, analysis of tHcy, α-synuclein 
depositions and loss of midbrain and striatal TH and DAT are planned in 
order to determine whether COMT inhibition has vascular and neuronal 
protective properties. 
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